Inhalation exposure technology, dosimetry, and regulatory issues.
Inhalation toxicology technology has provided the scientific community with important advances in studies of inhaled toxicants. These advances include new and more efficient exposure systems (e.g., flow-past nose-only exposure systems), and improved approaches to inhalation chamber environmental control (e.g., temperature, humidity, air quality). Practical problems and approaches to testing and operating inhalation exposure systems and the advantages and disadvantages of the major inhalation exposure types (e.g., whole-body, nose-only) are discussed. Important aspects of study design, such as high level particulate exposures resulting in large lung burdens (e.g., greater than or equal to 2 mg/g of lung), slowed pulmonary clearance rates, and nonspecific toxicity are considered, along with practical issues of comparative dosimetry. Regulatory guidelines have continued to present challenges in designing and conducting acute, subchronic, and chronic inhalation studies. The important regulatory issue of performing acute inhalation toxicity studies at high aerosol concentrations and "respirable" particle size distribution is discussed.
Dorato
M A
MA
Toxicology Division, Lilly Research Laboratories, Eli Lilly and Company, Greenfield, Indiana 46140.
Wolff
R K
RK
D000280:Administration, Inhalation; D000336:Aerosols; D000818:Animals; D001273:Atmosphere Exposure Chambers; D004305:Dose-Response Relationship, Drug; D006801:Humans; D012107:Research Design; D014116:Toxicology / Q000379:methods*; D014481:United States; D014484:United States Environmental Protection Agency
D000336:Aerosols